置顶推文
Ed Starkiller 🍥
21.7K posts


@amitisinvesting I believe we are seeing "new comers" take market share from Open AI as other LLMs are becoming way efficient and have better inteligence
English

Stocks are down big this morning on a WSJ report that OpenAI missed internal revenue targets at the end of 2025.
Few thoughts on why this might not be as bad as it is being interpreted:
- Part of the reason OpenAI did not meet its revenue backlog is because they did not have the proper compute needs. Jassy, Dario, and Altman have all said if they have more compute, they could grow faster. The bottleneck of energy/power/land seems to be a much bigger story than “missing revenue targets” because if the compute constrains are the reason for the miss, that’s an issue with supply, not demand.
- Maybe OpenAI missed internal forecasts because of $GOOGL and Anthropic seriously beginning to take marketshare. If that is true, that is NOT bearish semis/ai, that is more bearish OpenAI. The compute will just shift from OpenAI spending to Anthropic and Google spending. So, if OpenAI cancels a datacenter, it’s bad for the parties involved but if Google ends up taking up that datacenter, the same money continues to be spent on all the different providers that go into building out that compute.
- $SOXX just did 18 green days in a row. It was looking for ANY reason to sell off. Obviously some names have just gotten way ahead of themselves, for example $ARM, which began to trade at 70 p/s. The WSJ article may have been what was needed to give a reason to a selloff which quite frankly did not need a reason after the run it’s had.
Overall, feels more like a general headline about a company not fully living up to its expectations vs a systematic issue around compute constraints.
Big Tech reports on Wednesday and all eyes will be on what they have to say around capex, roi, growth, and more.
$NVDA $AMD $MSFT $META $ORCL

English

@StockMKTNewz and that's the main reason I own an iPhone.
English

@f1trollofficial it would be hilarious that the RB versiom works better than Ferrari's 🤡
English

@DiscussingFilm Jabba's son is going through his Ozempic's phase
English

@AutismCapital This was my first, proper introduction to the FF series. It was amazing.
English

@Mr_Derivatives It wouldn't be crazy to see futures flat. Trump's reaction so far has been to make a Strait of Hormuz blockade of their own to prevent passage from Iran and their allies
English

@Mr_Derivatives @youtubedevon just look at that RPM on his Youtube account. Is insane. That's not the average.
English

@youtubedevon The amount of work tweeting vs. the amount of work producing/editing/presenting videos.
Big diff.
English

On X I have gotten 60 million impressions. Total payout $1,800.
On YouTube I got 27 million views on one of my channels. It made $250,000.


Bright..@brighw3b
1million followers on X or 1million subscribers on YouTube?
English

@F1Tornello @MateuszMrz8 le faltó incluir a Hannah en ese combo
Español

#F1 Un ‘dream team’ completo se habrá ido de Red Bull cuando salga Lambiase. Horner, Marko, Wheatley, Marshall, Lambiase, Newey y Courtenay. Sólo quedará (?) Max 🏁
Foto vía @MateuszMrz8

Español

@TheLongInvest The disconnection of $TMDX share price since the start of the Iran war has been astonishing
English

@mathlonning tell me about it.. It is surprising to see that with those doomsday market accounts. If you are telling me that the market will crash without any chance of recovering, why would you sell me a course?
English

@Mr_Derivatives Thanos looks like a hippie from the 60s in comparison
English

@JonahLupton @PeptideList or that doesn't even know what they actually do.
English

@PeptideList This is scary and it’s why the industry needs regulation and oversight. Too many people using peptides and too many people that want to start using peptides but we can’t trust the sources or the sellers.
English

The New Yorker just lab-tested research peptides from a popular online vendor.
BPC-157: contained lead.
TB-500: contained endotoxins.
CJC-1295: less than 42% of the labeled dose.
This is what people are injecting into their bodies.
The peptides aren't the problem. The supply chain is. This is exactly why the FDA reclassification matters moving these compounds into regulated compounding pharmacies with cGMP standards and real quality control.

English

@JonahLupton @WallStAction Exactly. Under $100 after Q4 25 results and FY26 guidance is unbelievable.
English

@Polymarket and with that.. almost half of the bitcoin thesis goes to the🗑️
English














